Fabry Disease

Overview and Epidemiology

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene (located at Xq22.1), which encodes the lysosomal enzyme alpha-galactosidase A. Deficient or absent enzyme activity leads to progressive accumulation of globotriaosylceramide (Gb3, also called GL-3) in the lysosomes of vascular endothelium, cardiomyocytes, renal tubular cells and podocytes, Schwann cells, dorsal root ganglia, and corneal epithelium. This multi-organ substrate buildup drives the characteristic cascade of neuropathic pain, angiokeratomas, corneal opacities, and progressive damage to the heart, kidneys, and central nervous system that defines the disease.

Prevalence in the classic male form is estimated at 1 in 40,000 to 60,000. When late-onset cardiac and renal variants are included — identified through screening populations — estimates rise to as high as 1 in 3,000, suggesting that Fabry disease is substantially underdiagnosed in the general population. The disease was first independently described in 1898 by Johannes Fabry, a German dermatologist, and William Anderson, a British surgeon; it is therefore also known as Anderson-Fabry disease. Over 1,000 pathogenic GLA variants have been identified to date, with missense mutations predominating.

The X-linked inheritance pattern has critical clinical implications. Males are hemizygous — carrying a single mutated X chromosome — and in the classic form have near-zero enzyme activity, producing the full disease phenotype. Females are heterozygous, and random X-inactivation (lyonization) determines which allele is active in each cell. This results in variable expression: 50–70% of heterozygous females develop significant disease manifestations and are patients in their own right, not merely asymptomatic carriers. This historical misclassification of females as unaffected carriers led to underdiagnosis and undertreatment that persists in many healthcare settings today.

Back to Table of Contents

Molecular Pathogenesis and Gb3 Accumulation

GLA gene mutations cause loss of alpha-galactosidase A function, which normally cleaves the terminal galactose from globotriaosylceramide (Gb3). When this cleavage step fails, Gb3 accumulates progressively within lysosomes of multiple cell types throughout the body. The deacylated form, lyso-Gb3 (globotriaosylsphingosine), also accumulates and is biologically active: it sensitizes pain receptors by upregulating TRPV1 channels in sensory neurons (driving neuropathic pain), activates fibroblasts to produce fibrosis, and promotes endothelial dysfunction and systemic inflammation.

The pathological consequences of Gb3 accumulation unfold across multiple organ systems. In the vasculature, Gb3 deposition in endothelial cells triggers inflammation, promotes thrombosis, narrows lumens, and produces ischemia that manifests as stroke, transient ischemic attack, and cardiac events. In the heart, Gb3 accumulates in cardiomyocytes and causes hypertrophic cardiomyopathy with concentric left ventricular hypertrophy, a shortened PR interval, and arrhythmias. In the kidney, Gb3 in podocytes and tubular cells initiates proteinuria that progresses to chronic kidney disease and end-stage renal disease. In the nervous system, Gb3 in dorsal root ganglia Schwann cells produces small fiber neuropathy and the severe neuropathic pain that is often the earliest and most disabling symptom in affected children.

Genotype-phenotype correlations are meaningful but imperfect. Nonsense mutations, frameshifts, and splice-site variants that abolish enzyme production cause the classic early-onset phenotype with full multi-system involvement beginning in childhood. Missense mutations that allow partial residual enzyme activity — typically 1–15% of normal — produce late-onset phenotypes: the cardiac variant (hypertrophic cardiomyopathy presenting in the fifth or sixth decade without childhood symptoms) and the renal variant. Amenability to migalastat, an oral pharmacological chaperone, depends on whether a specific missense mutation creates a pocket in the misfolded enzyme that can be stabilized by the drug — this must be tested in cell-based assays for each individual mutation and is catalogued in the GalNet database.

Back to Table of Contents

Classic Fabry Phenotype: Childhood and Adolescent Features

Neuropathic pain is the cardinal early symptom and often the first manifestation, with onset typically between ages 3 and 10 years. Patients experience severe episodic burning, lancinating, or electric-shock pain in the hands and feet — a pattern called acroparesthesia, meaning pain localized to the extremities. Crises are triggered by fever, physical exercise, emotional stress, and temperature extremes (both heat and cold). Episodes can be incapacitating, lasting hours to days, and are frequently misattributed to "growing pains," rheumatic fever, appendicitis, or psychosomatic illness — contributing to diagnostic delays of a decade or more. Skin biopsy demonstrates reduced intraepidermal nerve fiber density on immunofluorescence, confirming small fiber neuropathy as the substrate.

Hypohidrosis and anhidrosis — impaired or absent sweating — are present in most hemizygous males. Affected children cannot thermoregulate normally through sweating, leading to heat intolerance, exercise intolerance, and school avoidance. Overheating during physical activity or in warm environments can trigger pain crises and is a significant quality-of-life burden. Angiokeratomas are dark-red to purple, non-blanchable papular vascular skin lesions that appear in adolescence and early adulthood, clustering in the "bathing-suit distribution": the umbilical area, scrotum or labia, inner thighs, buttocks, and lower abdomen. They also occur on the trunk, periumbilical skin, and occasionally lips and fingertips. Angiokeratomas increase in number and size with age and, while not dangerous in themselves, are visually striking and pathognomonic for classic Fabry disease (and a small number of other lysosomal storage disorders).

Corneal verticillata — a whorl-shaped or vortex-patterned epithelial opacity visible only on slit-lamp examination — is present in virtually all hemizygous males and most heterozygous females. It does not impair vision and causes no symptoms, but it is a critical diagnostic sign: its presence in a young person with unexplained pain, stroke, or cardiac hypertrophy should immediately prompt Fabry evaluation. Drug-induced corneal verticillata (from amiodarone or chloroquine) is the main differential. Gastrointestinal symptoms — early satiety, abdominal cramping, nausea, diarrhea, and alternating bowel habits — arise from Gb3 accumulation in enteric ganglia and vasculature and are common in childhood and adolescence. High-frequency sensorineural hearing loss and tinnitus occur in many patients and can progress over time, requiring periodic audiology evaluation.

Back to Table of Contents

Multisystem Involvement: Cardiac, Renal, Neurological, and Stroke

Cardiac disease is the leading cause of premature death in Fabry disease. Gb3 accumulation in cardiomyocytes causes concentric left ventricular hypertrophy (LVH) — a pattern of hypertrophic cardiomyopathy (HCM) that is indistinguishable from sarcomeric HCM on echocardiography alone. The Fabry HCM signature includes a characteristically shortened PR interval (reflecting conduction pathway Gb3 deposition) alongside LVH, a combination that should prompt alpha-galactosidase A enzyme testing in any young man presenting with unexplained cardiac hypertrophy. Cardiac disease progresses to diastolic dysfunction and heart failure as the myocardium stiffens from Gb3 load and subsequent fibrosis (detectable as late gadolinium enhancement on cardiac MRI — a particularly poor prognostic sign). Arrhythmias are common: sinus node dysfunction, atrioventricular block (requiring pacemaker implantation in some patients), atrial fibrillation, and ventricular arrhythmias with risk of sudden cardiac death. The cardiac variant of Fabry disease, caused by missense mutations with partial residual enzyme activity, presents in the fifth or sixth decade with isolated LVH and few or no childhood features and accounts for a substantial proportion of Fabry diagnoses made through HCM evaluation programs.

Renal disease begins insidiously with microalbuminuria from podocyte Gb3 accumulation, progresses to overt proteinuria as glomerular filtration is compromised by glomerulosclerosis and tubulointerstitial fibrosis, and advances to chronic kidney disease and end-stage renal disease (ESRD) requiring dialysis or transplantation — typically by the fourth or fifth decade in untreated classic males. Renal biopsy reveals lipid-laden foam cells (Gb3-engorged podocytes) and, on electron microscopy, the pathognomonic "zebra bodies" — lamellated electron-dense inclusions within lysosomes. Renal transplantation successfully restores kidney function and does not preclude continuation of enzyme replacement therapy for cardiac and neurological benefit.

Stroke and cerebrovascular disease occur at a 6- to 12-fold increased rate compared to the general population. Both ischemic (from Gb3-driven small vessel disease and cardiac embolism) and hemorrhagic strokes are reported, with the mean age of first stroke in Fabry males approximately 40 years — far younger than typical population-attributable stroke. A distinctive cerebrovascular feature is dolichoectasia of the vertebrobasilar system: tortuosity and dilation of the basilar artery visible on MRI, reflecting Gb3 accumulation in the vessel wall. The "pulvinar sign" — T1 hyperintensity in the posterior thalamus on MRI — has been described as a Fabry-specific neuroimaging finding, though it is not universally present. Posterior circulation strokes predominate. White matter lesions and lacunar infarcts accumulate over time. Retinal vessel tortuosity (another expression of vascular dolichoectasia) and posterior spoke-shaped cataracts are additional ophthalmological findings.

Back to Table of Contents

Fabry Disease in Female Carriers: Not "Just Carriers"

Decades of medical literature incorrectly labeled heterozygous females as "asymptomatic carriers" — women who harbor a GLA mutation but are protected from disease by their second, normal X chromosome. Current evidence comprehensively refutes this view: 50–70% of heterozygous females develop significant Fabry disease manifestations requiring medical attention, and virtually all have at least one detectable sign of the disease (corneal verticillata). Females are patients, not bystanders, and must be offered the same diagnostic evaluation and treatment access as affected males.

The key biological determinant of phenotype in females is random X-inactivation (lyonization). In each somatic cell, one X chromosome is stably inactivated early in development. If inactivation happens to favor the mutated allele more than expected by chance (skewed inactivation), the effective enzyme deficiency is deeper and clinical manifestations are more severe — approaching those of hemizygous males. Conversely, favorable inactivation patterns can produce near-asymptomatic females. Because each individual's pattern of X-inactivation is established in early embryogenesis and varies across tissues, the same GLA mutation can produce widely divergent phenotypes across female relatives.

Females with Fabry disease commonly develop corneal verticillata (near-universal — the most reliable screening sign in females), neuropathic pain and acroparesthesia (frequent), hypertrophic cardiomyopathy (the leading cause of morbidity in heterozygous females), renal involvement with proteinuria and CKD (generally less severe and slower-progressing than in males), and stroke (elevated risk — some studies suggest stroke burden in females is greater than previously recognized). Angiokeratomas occur but are less prominent than in males.

A critical diagnostic pitfall: alpha-galactosidase A enzyme activity is normal in up to 30–40% of heterozygous females due to favorable X-inactivation, making enzyme activity an unreliable screening test for females. GLA gene sequencing is required for diagnosis in any female with a family history of Fabry disease or compatible clinical findings. Lyso-Gb3 (plasma globotriaosylsphingosine) is elevated in virtually all affected females regardless of enzyme activity level and is the preferred biomarker for diagnosis confirmation and treatment monitoring. Management in females follows the same principles as in males: enzyme replacement therapy or migalastat (for amenable mutations) plus organ-specific management — females must not be excluded from disease-modifying treatment based on a presumed milder phenotype.

Back to Table of Contents

Diagnosis: Enzyme Activity, Genetic Testing, and Biomarkers

In males, the primary diagnostic test is measurement of alpha-galactosidase A enzyme activity, which can be performed in dried blood spots (DBS), plasma, or leukocytes. Near-zero activity in hemizygous classic males is diagnostic. DBS testing is convenient for screening and is now included in expanded newborn screening programs in some US states and internationally (notably Taiwan's pilot program, which found Fabry disease in approximately 1 in 1,500 male newborns, substantially higher than clinically ascertained prevalence and confirming widespread underdiagnosis of late-onset variants). For borderline or uncertain results, leukocyte-based enzyme assays provide greater analytical reliability.

In females, enzyme activity is unreliable as a diagnostic test — up to 40% of heterozygous females have normal activity due to favorable X-inactivation. GLA gene sequencing is required for diagnosis in females. Sequencing also serves critical functions in both sexes: identifying the specific pathogenic variant, determining amenability to migalastat (the GalNet database lists variants that qualify for the oral pharmacological chaperone), guiding genotype-phenotype prognosis counseling, and enabling accurate testing of first-degree relatives. Once an index case is identified, cascade testing should be offered to all first-degree family members — males receive enzyme activity DBS plus sequencing, females receive sequencing.

Lyso-Gb3 (globotriaosylsphingosine, plasma) is the most clinically versatile biomarker in Fabry disease. It is elevated in all affected males and in virtually all affected females regardless of enzyme activity level, making it the preferred tool for (a) confirming diagnosis in females with equivocal enzyme activity, (b) monitoring treatment response in both sexes, and (c) correlating with disease burden and progression. Urine Gb3 is elevated in males but less reliable in females. At the time of diagnosis, a comprehensive organ assessment should be performed: 12-lead ECG (short PR interval, LVH voltage criteria, arrhythmia detection), echocardiogram and cardiac MRI with late gadolinium enhancement (to detect fibrosis — a critical prognostic sign indicating irreversible myocardial damage), serum creatinine and eGFR, urine protein/creatinine ratio, ophthalmology slit-lamp examination for corneal verticillata and posterior cataracts, audiology evaluation, and MRI brain with DWI to assess for stroke, white matter lesions, and basilar dolichoectasia.

Back to Table of Contents

Treatment: Enzyme Replacement Therapy, Migalastat, and Organ Protection

Enzyme Replacement Therapy (ERT) is the standard of care for Fabry disease and has been available since 2001. Both approved ERT agents supply recombinant human alpha-galactosidase A delivered by intravenous infusion every two weeks. Agalsidase beta (Fabrazyme, Sanofi Genzyme; FDA-approved 2003) is dosed at 1 mg/kg and is the agent approved in the United States. Agalsidase alfa (Replagel, Shire/Takeda; EMA-approved, 0.2 mg/kg) is available in Europe and other markets but is not FDA-approved for marketing in the US. Clinical trials by Eng et al. (2001, agalsidase beta) and Schiffmann et al. (2001, agalsidase alfa) established ERT efficacy, demonstrating Gb3 clearance from renal, cardiac, and vascular endothelial cells. ERT is most effective when initiated before irreversible organ damage — particularly before cardiac fibrosis (late gadolinium enhancement on MRI) and before established renal fibrosis — is present. It stabilizes renal function and can reduce or stabilize LVH in early-stage disease; it does not substantially reverse established fibrosis. Anti-drug antibodies can develop, particularly in males with null mutations and no residual endogenous enzyme, and are associated with attenuated treatment response.

Migalastat (Galafold, Amicus Therapeutics; FDA-approved 2018, EMA-approved 2016) is the first approved oral disease-modifying therapy for Fabry disease. It is a pharmacological chaperone — a small molecule that binds the active site of mutant alpha-galactosidase A in the endoplasmic reticulum and Golgi, stabilizing the misfolded protein and allowing it to traffic correctly to the lysosome where it becomes active at lysosomal pH. Migalastat is taken as a single oral capsule every other day (to allow enzyme activity to peak between doses). Its critical limitation is selectivity: it works only for amenable GLA mutations — approximately 35–50% of known missense mutations — in which the mutant enzyme retains a stabilizable active-site pocket. Amenability must be determined for each specific variant using validated cell-based assays; the GalNet database maintains a curated list of amenable variants. The ATTRACT trial demonstrated non-inferiority of migalastat to ERT in patients with amenable mutations. Major advantages over ERT include oral administration (eliminating biweekly infusions), avoidance of infusion reactions, and no anti-drug antibody issues. Migalastat is approved for adults aged 16 and older with confirmed amenable mutations.

Management of neuropathic pain requires specific pharmacological intervention, as standard analgesics are typically inadequate. Carbamazepine has the strongest evidence base, reducing the frequency and severity of pain crises in controlled studies. Gabapentin, pregabalin, and mexiletine are additional options. Opioids should be avoided for chronic pain management due to limited efficacy and risk of dependence. Organ-specific management is essential alongside disease-modifying therapy: ACE inhibitors or angiotensin receptor blockers (ARBs) for proteinuria and kidney protection; antiplatelet agents and statins for stroke risk reduction; antiarrhythmic agents, pacemakers, or implantable cardioverter-defibrillators for cardiac arrhythmias; and renal transplantation for ESRD. Importantly, renal transplantation does not negate the need for ERT, which must be continued for cardiac and neurological benefit. The decision to initiate, continue, or switch disease-modifying therapy should be made in partnership with a metabolic disease specialist experienced in Fabry disease.

Back to Table of Contents

Newborn Screening, Family Cascade Testing, and Monitoring

Newborn screening for Fabry disease using dried blood spot alpha-galactosidase A activity is now included in expanded newborn screening panels in some US states and several countries. Taiwan's prospective newborn screening program, one of the largest in the world, identified Fabry disease in approximately 1 in 1,500 male newborns — far exceeding prior clinically ascertained prevalence estimates and confirming that late-onset variants are vastly underdiagnosed in the general population. Early identification through newborn screening enables presymptomatic monitoring and timely treatment initiation before irreversible organ damage accumulates — the window of greatest therapeutic benefit. Positive DBS screens require reflex GLA gene sequencing to confirm the pathogenic variant, determine disease type, and distinguish classic from late-onset mutations.

Cascade family testing is a high-yield strategy for identifying undiagnosed Fabry disease. Once an index case is confirmed, all first-degree relatives — parents, siblings, and children — should be offered testing. Male relatives receive alpha-galactosidase A enzyme activity (DBS or leukocytes) plus GLA sequencing; female relatives require GLA sequencing regardless of enzyme activity, as activity may be normal due to favorable X-inactivation. Genetic counseling should accompany all testing to help families understand X-linked inheritance, recurrence risks, and implications for family planning. Prenatal testing and preimplantation genetic diagnosis are available for families who desire them.

Monitoring on treatment should occur at 6-month intervals and include: plasma lyso-Gb3 (treatment response biomarker), urine protein/creatinine ratio, eGFR and serum creatinine (renal progression), echocardiogram and annual or biennial cardiac MRI with late gadolinium enhancement (cardiac fibrosis progression — a key endpoint for treatment decisions), 24-hour Holter monitoring (arrhythmia surveillance), and MRI brain (new white matter lesions or stroke). Audiology and ophthalmology evaluations should be performed annually. Transition of care from pediatric to adult specialist teams at ages 16–18 years requires deliberate coordination to ensure uninterrupted ERT or migalastat supply, transfer of monitoring records, and engagement with an adult metabolic disease team familiar with Fabry disease. Gaps in treatment during transition are associated with accelerated organ damage.

Back to Table of Contents

Key Research Papers

  1. Eng CM, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345(1):9-16. PMID: 11439963
  2. Schiffmann R, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743-2749. PMID: 11386930
  3. Hughes DA, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease. J Med Genet. 2017;54(4):288-296. PMID: 27834756
  4. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. PMID: 20920228
  5. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93(4):528-535. PMID: 17309904
  6. Wanner C, et al. Agalsidase beta treatment of older patients with Fabry disease. Am J Med. 2012;125(3):289-297. PMID: 22340929
  7. Sims K, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Stroke. 2009;40(3):788-794. PMID: 19150865
  8. Arends M, et al. Characterisation of classical and nonclassical Fabry disease: a multicentre study. J Intern Med. 2017;282(4):352-363. PMID: 28671317
  9. Mehta A, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236-242. PMID: 15025684
  10. Ortiz A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-427. PMID: 29338930
  11. Smid BE, et al. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015;52(4):262-268. PMID: 25604084
  12. Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2021;32(10):2482-2492. PMID: 34290095

Back to Table of Contents

Connections